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Pressure Relieving Support Surfaces: a
Randomised Evaluation 2 (PRESSURE 2):
using photography for blinded central
endpoint review
Elizabeth McGinnis1 , Isabelle L Smith1, Howard Collier1, Lyn Wilson2, Susanne Coleman1, Nikki Stubbs3,
Sarah Brown1, Rachael Gilberts1, Valerie Henderson4, Kay Walker5, E. Andrea Nelson6, Jane Nixon1* and on behalf
of the PRESSURE 2 Trial Group
Abstract
Background: PRESSURE 2 is a randomised evaluation of the clinical and cost-effectiveness of two types of mattress
for the prevention of pressure ulcers (PUs). The primary clinical endpoint was time to development of a category
≥2 PU. The current ‘gold standard’ for PU identification is expert clinical assessment. Due to the mattress
appearance, a blinded assessment of the endpoint is not possible. This poses a risk to the internal validity of the
study. A possible approach is to use photographs of skin sites, with central blinded review. However, there are
practical and scientific concerns including patients’ consent to photographs, burden of data collection, photograph
quality, data completeness and comparison of photographs to the current ‘gold standard’. This paper reports the
findings of the PRESSURE 2 photographic validation sub-study.
Method: Where consent was obtained, photographs were taken of all category ≥2 PUs on the first presentation to
assess over-reporting, and for the assessment of under-reporting, a random sample of 10% patients had an
assessment by an independent clinical assessor who also photographed two skin sites. The staff were trained in
taking and transferring photographs using standardised procedures and equipment. A card included in the
photograph recorded participant details and a ‘greyscale’ for correction of white balance during processing. Three
blinded reviewers assessed the photographs and rated how confident they were in their assessment.
Results: The trial recruited 2029 patients; 85% consented to photography, and 532 photographs were received and
used in the blinded central review. The level of confidence varied by skin classification with more confidence
observed when the skin was assessed as being less severe than a category ≥2 PU. Overall, there was a very good
reliability compared to the gold standard expert clinical assessment (87.8%, kappa 0.82).
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Conclusion: Study findings have usefully informed the scientific and practical issues of blinded assessment of PU
status to reducing the risk of bias in medical device trials. The reliability of central blinded expert photography was
found to be ‘very good’ (PABAK). Photographs have been found to be an acceptable method of data validation for
participants. Methods to improve the quality of photographs would increase the confidence in the assessments.
Trial registration: ISRCTN Registry ISRCTN01151335. Registered on 19 April 2013
Keywords: Pressure ulcer, Wound photography, Blinded outcome assessment, Randomised controlled trial
Background
PRESSURE 2 was a randomised controlled trial (RCT),
evaluating the clinical and cost-effectiveness of two types
of pressure-relieving mattress frequently used in pres-
sure ulcer prevention practice [1, 2]. Alternating pres-
sure mattresses (APMs) were compared to high-
specification foam mattresses (HSFM) with patients at
high risk of pressure ulcer (PU) development in acute
secondary care settings in the UK. The primary endpoint
of the clinical study was the time to development of new
category ≥2 PUs [3]; secondary endpoints included time
to development of new category ≥1 PUs and new cat-
egory ≥3 PUs, time to healing of existing category 2 PU
and cost-effectiveness. The protocol for the clinical trial
and the endpoint validation methods are available else-
where [4, 5]; the clinical findings are also published [1].
It is recognised that blinding of patients and carers is
the ‘Achilles heel’ of most RCTs in wound care [6].
Medical devices such as dressings and pressure-relieving
equipment used in wound care and PU prevention differ
visually such that it is usually impossible to mask partici-
pants. Blinding of outcome assessors can usually be
achieved by removing the device prior to the outcome
assessment. Unfortunately, while this is possible with a
dressing or off-loading device, in most cases, it is not
practical or ethical to temporarily move the patient to
another mattress for blinded outcome assessment.
The additional challenge is the diagnosis of PUs and in
particular pre-clinical markers. Although there are a few
studies which identify pre-clinical markers associated
with PU development [7–9], the lack of evidence for the
pathophysiology of PU and an objective laboratory diag-
nosis has resulted in the ‘gold standard’ for trial end-
point assessment as clinical assessment by trained
research nurses [10, 11].
The diagnosis of a category ≥2 PU can also be subject-
ive. The appearance of a category 2 PU may be similar
to other wounds, e.g. those caused by moisture [12, 13].
There is, therefore, a risk of bias if the nurses have an
explicit or covert preference for one or other mattress
types and misclassify a wound. This could be a threat to
the internal validity of the study.
Various alternative approaches to minimise bias and
overcome the risk of over- or under-reporting of PU
were explored which are reported in the protocol paper
[5]. As none of these appeared to be satisfactory, we de-
signed a photography validation sub-study to establish a
method of blinded outcome assessment to address both
the scientific and practical issues.
Methods
As full details of the methods are already available [5], a
brief summary is now provided.
The main aim of the PRESSURE 2 photography sub-
study was to assess the feasibility of using blinded expert
central photography review to quantify potential bias in
the reporting of the presence of a category ≥2 PU (PRES
SURE 2 trial endpoint).
The primary objectives were to assess the following:
1. Over-reporting of PUs category ≥2
2. Under-reporting of PUs category ≥2
The secondary objectives were to assess the following:
1. Rates of consent/potential impact upon trial
recruitment
2. Acceptability to patients
3. Compliance with photographs
4. Compliance with the secure transfer of photographs
between the research site and the Clinical Trials
Research Unit (CTRU)
5. Quality of photographs and confidence of
photographic review
Patients at high risk of developing PUs were recruited
from acute in-patient facilities.
During recruitment, optional additional consent for
photographs was taken. Photographs were taken as
follows:
a) For all category ≥2 PUs, at the first observation by
clinical research nurses (subject to patient consent
to photography)
b) For a torso and heel pressure area, by an
independent clinical assessor from a 10% random
sample of patients (subject to patient consent for
photography)
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As this was exploratory, no formal sample size was cal-
culated. Prior to the start of the study, an estimate of a
maximum of 1653 photographs corresponding to 1080
PU photographs and 573 PU-free photographs would be
received and reviewed, based on the original trial sample
size of 2954 participants, 5.7% pre-existing category 2
PU and 20.5% incidence of category ≥2 PU. As the event
rate was lower than anticipated, by the end of the study,
an anticipated maximum number of photographs was
918, based on the number of category 2 PUs at baseline
reported, new category ≥2 and those taken due to ran-
dom sample selection.
The choice of camera was made following advice from
a professional medical photographer and in consider-
ation of the number needed, budget and ease of use by
non-professional photographers. All photographs were
taken with the chosen camera model (Canon IXUS
510HS) to ensure consistency of colour and image
quality.
Photographs were taken by clinical research nurses
and the independent clinical assessors, who had received
training in the use of the camera, and they followed the
procedures outlined in a work instruction. Photographs
were transferred to the CTRU via a secure transfer
process and white balance adjusted for variation in light-
ing conditions using the Adobe® Lightroom software
(Adobe Systems Incorporated, San Jose, CA, USA).
A corresponding ‘gold standard’ clinical skin assess-
ment was made by the clinical research nurse and the
independent clinical assessor, for comparison with the
central expert blind photographic review.
Photograph review sessions were organised; each
photograph was simultaneously assessed by 3 of the 4
central blinded expert assessors (SC, LW, NS, EM) to
ensure standardisation of image conditions. The photo-
graphs (category 2 images from clinical research nurses
and 2 skin site images from the independent clinical as-
sessors) were batched together for each central blinded
expert session and presented in an ad hoc order. HC
oversaw each session and ensured that all photographs
were classified by each blinded expert assessor inde-
pendently and that assessors were blind to the corre-
sponding clinical assessment and the other central
blinded expert assessors.
The PU skin assessment is normally a clinical process
which includes a holistic assessment and manual exam-
ination of the skin. Additionally, the photograph quality
can be poor, e.g. dark or blurred. In order to capture un-
certainty, the central blinded expert assessors allocated a
confidence rating to their skin status decision, using a
scale of 0–10 (where 0 = ‘not confident at all’ and 10 =
‘very confident’).
For the assessment against the gold standard clinical
assessment, one skin classification was derived from the
resulting three central blinded expert assessor classifica-
tions. The derived classification was based on the agree-
ment of at least two blinded assessors. All derived
central blinded expert assessor classifications were com-
pared against the corresponding clinical assessment.
Analysis of over-reporting is presented as the propor-
tion of agreement between clinical skin assessments by
trained clinical research nurses at the scheduled trial as-
sessment visit and the central expert blinded assessor re-
view of category 2 PU photographs.
Analysis of under-reporting is presented as follows:
a) The proportion of the agreement between the ‘gold
standard’ clinical skin assessment by the
independent assessors and the central expert
blinded assessor review of photographs taken of the
10% random sample
b) The proportion of the agreement between the ‘gold
standard’ clinical assessment by the clinical research
nurse at the scheduled trial assessment visit and the
clinical assessment by the independent assessor at
the 10% random sample visits.
Compliance was monitored and adjusted to ensure the
10% proportion of patients were selected.
Where comparisons included all categories of PU, the
kappa statistic was calculated using the results from the
central blinded expert assessors and the clinical assess-
ments. The kappa statistic is defined as the proportion
of agreement after the chance agreement is removed
from consideration [14]. In addition, the prevalence and
bias-adjusted kappa (PABAK) [15] was also calculated to
account for the low prevalence of category 2 PUs and
any bias between assessors.
Rates of consent, acceptability of and compliance with
photography were reviewed and reported. The quality of
photographs and the independent assessors’ confidence
were also reported.
Results
The PRESSURE 2 trial recruited 2029 patients between
August 2013 and November 2017. The full clinical re-
sults of the trial are already published [1].
At baseline, 145 patients had a total of 177 category 2
PUs. During the trial, 160 patients developed 213 cat-
egory ≥2 PUs. A maximum of 390 photographs were
therefore expected from n = 305 patients. Photographs of
category ≥2 (at baseline and new events) received were
248 (63.6%): 103 of 180 (57%) expected from the APM
arm and 145 of 210 (69%) expected from the HSFM
arm. Reasons for the 142 missing photographs were
mainly due to the lack of consent, 32.3% were because
patients had not provided consent at baseline and 17.5%
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due to verbal refusal at the time of the photograph re-
quest (Table 5).
Primary objective 1: Over-reporting of PUs category ≥2
Central blinded expert photography review versus ‘gold
standard’ clinical research nurse clinical assessment
The overall agreement between the central blinded ex-
pert photography review assessment and the ‘gold stand-
ard’ clinical research nurse clinical assessment of
category ≥2 was 83.5% (207/248, 95% CI = (78.9% to
88.1%)). This represents agreement of 88.3% (91/103,
95% CI = (82.1% to 94.5%)) in the APM arm and 80.0%
(116/145, 95% CI = (73.5% to 86.5%)) in the HSFM arm
(Table 1).
Primary objective 2: Under-reporting of PUs category ≥2
A total of 264 (13.0%) patients were selected for inclu-
sion in the 10% random sample to be assessed by the in-
dependent clinical assessor. A maximum of 528
photographs were expected (2 photographs per patient).
However, only 167 (63.3%) of these patients had an inde-
pendent clinical assessment, and of these, 142(85.0%)
were reported to have had photographs taken, with a
total of 284 (53.8%) photographs returned from 137
(51.9%) patients (Table 2). In terms of compliance with
the 10% random sample, the 167 of the patients who
had an independent clinical visit equates to 8.2% of the
intention-to-treat (ITT) population.
Central blinded expert photography review vs independent
clinical assessment
There was an agreement between the central blinded ex-
pert review photographs and independent clinical asses-
sor in 91.5% of cases (260/284) for all skin site
assessments (i.e. healthy, altered or category 1 PU, or
category ≥2). This is broken down into 90.5% (114/126)
agreement in the APM arm and 92.4% (146/158) agree-
ment in the HSFM arm.
The central blinded expert photograph reviewers iden-
tified 15 PUs category ≥2, of which only 6 were also
assessed by the independent clinical assessor as a PU
category ≥2, 2 were assessed as ‘not applicable’, 7 were
assessed as healthy, altered or category 1 PUs (see
Table 3). Conversely, there were 10 PUs category ≥2
assessed by the independent clinical assessor; 2 were
classified as healthy, altered or category 1 PUs; and 2
were unable to be determined by the central blinded ex-
pert photographic review.
The kappa statistic of 0.53 is in the region of ‘weak
agreement’ [16, 17] however is influenced by a small
proportion of PUs category ≥2 reported. The PABAK
statistic of 0.93 demonstrates ‘very good agreement’ of
photograph assessments compared to clinical
assessments.
All photographs—central blinded expert photography
review vs clinical assessment
The level of agreement between the central blinded ex-
pert photograph review and all clinical assessments was
87.8% (467/532). There were 222 PUs category ≥2
assessed on the central blinded expert photographic re-
view, and of these, 213 were also assessed by the clinical
assessors (i.e. clinical research nurses and independent
clinical assessors) as a PU category ≥2 (2 were assessed
as ‘not applicable’ and 7 as healthy, altered or category 1
PUs). Similarly, there were a total of 258 PUs category
≥2 reported by the clinical assessors, of which 38 were
classified as healthy, altered or category 1 PUs and 7
were unable to be determined through central blinded
expert photography review. The corresponding kappa
statistic is 0.82 (‘very good agreement’), and PABAK is
equal to 0.82 indicating that photographic assessment
has ‘very good agreement’ when compared with expert
clinical assessment.
Independent clinical assessor versus clinical research nurse
skin assessments
Skin assessments by the independent clinical assessor
were compared to the clinical research nurse clinical
skin assessment which was closest in time. The overall
Table 1 Summary of blinded central expert review assessments for photographs taken of PU category ≥2
APM HSFM Total
Blinded central expert review assessment
PU Category ≤1 6 (10.7%) 25 (17.2%) 36 (14.5%)
PU Category ≥2 91 (88.3%) 116 (80.0%) 207 (83.5%)
Unable to determine 1 (1.0%) 4 (2.8%) 5 (2.0%)
Total number of photographs reviewed 103 (100.0%) 145 (100.0%) 248 (100.0%)
Was at least one blinded central expert review assessment PU category≥ 2?
Yes 97 (94.2%) 129 (89.0%) 226 (91.1%)
No 6 (5.8%) 16 (11.0%) 22 (8.9%)
Total number of photographs reviewed 103 (100.0%) 145 (100.0%) 248 (100.0%)
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agreement was observed to be 94.6% (157/166) broken
down into 91.7% (66/72) agreement for patients in the
APM arm and 96.8% (91/94) agreement in the HSFM
arm.
There were 12 PUs category ≥2 assessed by the inde-
pendent assessor, and of these, 5 were reported as
healthy, altered or category 1 PUs by the clinical re-
search nurse (see Table 4). When broken down by mat-
tress group, all the category ≥2 PUs reported by the
independent clinical assessor but not by the clinical re-
search nurse were in the APM arm. Furthermore, there
were 4 skin sites that were assessed as a PU category ≥2
by the clinical research nurse that the independent as-
sessor categorised as healthy, altered or category 1 (1 in
the APM arm and 3 in the HSFM arm).
The kappa statistic was observed to be in the region of
‘moderate agreement’; however, this is influenced by the
small proportion of PUs category ≥2 observed. The
Table 2 Summary of independent clinical assessments for a random sample of patients
APM HSFM Overall
Skin verification sub-study visit conducted
Yes 72 (59.5%) 95 (66.4%) 167 (63.3%)
No 49 (40.5%) 48 (33.6%) 97 (36.7%)
Total 121 (100.0%) 143 (100.0%) 264 (100.0%)
Reason skin verification study visit not done
Missed by the independent clinical assessor 18 (36.7%) 18 (37.5%) 36 (37.1%)
Participant refused 1 (2.0%) 1 (2.1%) 2 (2.1%)
Participant too unwell 4 (8.2%) 2 (4.2%) 6 (6.2%)
Participant has been transferred to another eligible inpatient facility 1 (2.0%) 0 (0.0%) 1 (1.0%)
Patient has been discharged 9 (18.4%) 15 (31.3%) 24 (24.7%)
Patient has been transferred to an ineligible inpatient facility 1 (2.0%) 1 (2.1%) 2 (2.1%)
Participant has withdrawn from the trial 2 (4.1%) 2 (4.2%) 4 (4.1%)
Participant has died 3 (6.1%) 0 (0.0%) 3 (3.1%)
Did not receive study email 3 (6.1%) 3 (6.3%) 6 (6.2%)
Lack of staff capacity 7 (14.3%) 3 (6.3%) 10 (10.3%)
Reason unknown 0 (0.0%) 2 (4.2%) 2 (2.1%)
Other reasons 0 (0.0%) 1 (2.1%) 1 (1.0%)
Total 49 (100.0%) 48 (100.0%) 97 (100.0%)
If study assessment was conducted, were photographs attempted?
Yes 63 (87.5%) 79 (83.2%) 142 (85.0%)
No 9 (12.5%) 16 (16.8%) 25 (15.0%)
Total 72 (100.0%) 95 (100.0%) 167 (100.0%
If no photographs were taken, reason:
Consent for photos to be taken not obtained 9 (100.0%) 9 (56.3%) 18 (72.0%)
Participant no longer wants photos to be taken 0 (0.0%) 3 (18.8%) 3 (12.0%)
Participant does not want photos to be taken at this visit 0 (0.0%) 1 (6.3%) 1 (4.0%)
Not appropriate at this time 0 (0.0%) 2 (12.5%) 2 (8.0%)
Missing 0 (0.0%) 1 (6.3%) 1 (4.0%)
Total 9 (100.0%) 16 (100.0% 25 (100.0%)
Number of photographs received per patient
0 10 (13.9%) 20 (21.1%) 30 (18.0%)
1 2 (2.8%) 0 (0.0%) 2 (1.2%)
2 57 (79.2%) 67 (70.5%) 124 (74.3%)
3 2 (2.8%) 6 (6.3%) 8 (4.8%)
4 1 (1.4%) 2 (2.1%) 3 (1.8%)
Total number of patients who had verification study assessment 72 (59.5%) 95 (66.4%) 167 (63.3%)
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Table 3 Cross-tabulation of assessment by the independent clinical assessor and blinded expert central photography review
Blinded expert central photography review Kappak PABAKk
Healthy, altered or
Cat. 1 PU









254 (89.4%) 7 (2.5%) 3 (1.1%) 264
(93.0%)
0.53 0.93
Category 2, 3, 4 or U 2 (0.7%) 6 (2.1%) 2 (0.7%) 10 (3.5%)
N/A 4 (1.4%) 2 (0.7%) 1 (0.4%) 7 (2.5%)l
Missing 3 (1.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)






110 (87.3%) 3 (2.4%) 1 (0.8%) 114
(90.5%)
0.59 0.92
Category 2, 3, 4 or U 2 (1.6%) 4 (3.2%) 2 (1.6%) 8 (6.4%)
N/A 1 (0.8%) 1 (0.8%) 0 (0.0%) 2 (1.6%)
Missing 2 (1.6%) 0 (0.0%) 0 (0.0%) 2 (1.6%)






144 (91.1%) 4 (2.5%) 2 (1.3%) 150
(94.9%)
0.49 0.95
Category 2, 3, 4 or U 0 (0.0%) 2 (1.3%) 0 (0.0%) 2 (1.3%)
N/A 3 (1.9%) 1 (0.6%) 1 (0.6%) 5 (3.2%)
Missing 1 (0.6%) 0 (0.0%) 0 (0.0%) 1 (0.6%)
Overall 148 (93.1%) 7 (4.4%) 3 (1.9%) 158
(100.0%)
U unstageable
kKappa and PABAK calculated using only assessments where both the independent assessor and central review assessments were available
lIAD/moisture lesion (N = 5), dermatological skin condition (N = 1) and surgical wound/bruising (N = 1)
Table 4 Cross-tabulation of the overall clinical assessment by independent clinical assessor and clinical research nurse/practitioner
(CRN/P)
Independent assessor Kappa PABAK
Healthy, altered or category 1
PU





Healthy, altered or category 1
PU
150 (90.4%) 5 (3.0%) 155 (93.4%) 0.58 0.89
Category 2, 3, 4 or
unstageable
4 (2.4%) 7 (4.2%) 11 (6.6%)




Healthy, altered or category 1
PU
61 (84.7%) 5 (6.9%) 66 (91.7%) 0.58 0.83
Category 2, 3, 4 or
unstageable
1 (1.4%) 5 (6.9%) 6 (8.3%)
Overall 62 (86.1%) 10 (13.9%) 72 (100.0%)
HSFM CRN/
P
Healthy, altered or category 1
PU
89 (94.7%) 0 (0.0%) 89 (94.7%) 0.56 0.94
Category 2, 3, 4 or
unstageable
3 (3.2%) 2 (2.1%) 5 (5.3%)
Overall 92 (97.9%) 2 (2.1%) 94m
(100.0%)
mOne patient was excluded from the comparison with the clinical research nurse because no baseline or follow-up forms were received
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corresponding PABAK statistic of 0.89 overall is in the
region of ‘very good agreement’ (see Table 4).
Secondary objective 1: Rates of consent/potential impact
upon trial recruitment
Overall, 1711 (84.3%) patients in the ITT patient popula-
tion consented to photography. This was comparable in
both mattress groups with 860 (84.6%) patients allocated
to APM who had consented, and 851 (84.0%) patients al-
located to HSFM. There were no patients who reported
the photography element as a barrier to trial participa-
tion. It was noted that fewer consultees provided add-
itional consent to photographs: 80.8% of those
consented by consultees compared to 86.4% of those
who provided written or witnessed verbal consent also
consented to photographs.
Secondary objectives 2 and 3: Acceptability to patients
and compliance with photographs
There were 170 occasions where photographs of PUs
category ≥2 had not been attempted. The reasons for
these are summarised in Table 5. The most common
reason was consent for photographs had not been ob-
tained (N = 56, 32.9%). The reasons were reasonably bal-
anced between the two mattress groups although there
was a higher proportion in the HSFM arm where photo-
graphs were missed in error (N = 14, 14.3%) compared
to the APM arm (N = 7, 9.7%) (Table 5). In terms of the
10% random sample, of those patients who had an inde-
pendent clinical assessor visit (N = 167), the main reason
for non-completion of photographs was because consent
had not been obtained (N = 18, 72.0%).
Secondary objective 4: Compliance with secure transfer of
photographs between the research site and the trial
management centre
There were 25 protocol deviations reported relating to
the administration of photographs. These were the trial
generic email address used for photography transfer
(N = 11), greyscale card not being in the photograph
(N = 7), incorrect time of data collection (N = 3), photo-
graphs received from patients who had not provided ini-
tial written consent (N = 2), wrong camera used (N = 1)
and camera stolen (N = 1). Where the photographs were
transferred using the wrong email address, these were
deleted from the senders and receivers email accounts
and resent using the secure account. Where photographs
were received from patients who provided verbal agree-
ment at the time of the photography but had refused
photography during consent to study participation, these
were destroyed by the sender and receiver and excluded
from the analysis.
Secondary objective 5: Quality of photographs and
confidence in photography assessment
Overall, the reviewers tended to be more confident when
they assessed a photograph as healthy, altered or cat-
egory 1. Reviewer 1 gave a confidence score of at least 6
in 70.5% of cases compared to 55.5% of the photographs
they assessed as PU category ≥2. Reviewer 2 had a confi-
dence of at least 6 in 86.5% of photographs they assessed
as healthy, altered or category 1 compared to 75.6% of
those they assessed as PU category ≥2, and reviewer 3
had a confidence score of at least 6 for 79.5% of the
former compared to 68.6% of the photographs they
assessed as PU category ≥2. There was a very small
number of photographs with no assessment (n = 16), and
Table 5 Photography compliance for reported PU category ≥2
APM HSFM Overall
Reasons for photographs of category ≥ 2 PUs not being taken across all visits (includes re-attempts)
Consent for photographs to be taken not obtained 27 (32.1%) 34 (32.4%) 61 (32.3%)
Participants does not want photographs taken at this visit 16 (19.0%) 17 (16.2%) 33 (17.5%)
Not appropriate currently 12 (14.3%) 10 (9.5%) 22 (11.6%)
Missed in error 7 (8.3%) 14 (13.3%) 21 (11.1%)
Photo not taken due to logistical problems (e.g. camera unavailable, not enough time) 7 (8.3%) 8 (7.6%) 15 (7.9%)
Participant no longer wants photographs taken as part of this trial 5 (6.0%) 8 (7.6%) 13 (6.9%)
Pre-photography study set-up 2 (2.4%) 4 (3.8%) 6(.2%)
Reason unknown 2 (2.4%) 4 (3.8%) 6 (3.2%)
Dressing/cast in situ 2 (2.4%) 3 (2.9%) 5 (2.6%)
Camera technical problem 3 (3.6%) 0 (0.0%) 3 (1.6%)
Others 1 (1.2%) 2 (1.9%) 3 (1.6%)
Unable to reposition the patient 0 (0.0%) 1 (1.0%) 1 (0.5%)
Total 84 (100.0%) 105 (100.0%) 189 (100.0%)
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the main reason given for this was the poor quality of
the photograph.
Discussion
A potential imbalance was observed in the over-
reporting of PUs between arms indicating that PUs may
have been more likely to be over-reported in the HSF
arm by the clinical research nurses. However, the confi-
dence intervals for the level of agreement for each group
overlap. This needs to be considered alongside the un-
equal return of photographs of PUs category ≥2, i.e. a
lower return rate for the APM arm, and the diagnostic
uncertainty associated with central blinded expert pho-
tography review.
For the assessment of under-reporting of category≥2
PUs, there was a good agreement between the clinical
assessments and the blinded reviewers. However, the re-
sults of the independent clinical assessor versus the clin-
ical research nurses when broken down by intervention
arm suggest that there may be some under-reporting by
both the clinical research nurses and the independent
assessor. However, the sample size is too small to deter-
mine the level of under-reporting and to distinguish
whether there are any differences between the arms.
Moreover, there were time intervals between the two
clinical assessments. PUs, particularly category 1, are
known to develop and resolve within days or even hours
[6] which may be reflected in this variation in reporting.
Most patients at the time of recruitment consented to
photography. Slightly lower photography consent rates
were noted for consultee agreement; this may be due to
consultees being protective of the patient if they were
uncertain of their wishes.
Patient movements between care environments and
changes in capacity and consent were the main contrib-
utors to photographs not being taken by the independ-
ent clinical assessor. Compliance with the return of
photographs was greater than 50% but could have been
improved with better processes, e.g. use of improved pa-
tient tracking systems. The use of a photography-specific
email account may have resulted in some of the protocol
violations, and improved methods of secure file transfer
are currently being tested.
There were varying levels of confidence from the
blinded expert reviewers of the photographs, with more
confidence demonstrated in skin sites assessed as
healthy, altered or category 1. In only a very small num-
ber of photographs could no assessment be made. The
quality of the photographs taken was reflected in the
central reviewers’ confidence in the assessment. While
brief training and detailed work instructions were given
to participating sites, the poor quality of some of the im-
ages led the team to review the camera settings at sites
and during investigator meetings when possible. It was
noted that some of the cameras were not set according
to the work instruction. Considering the ease of use had
informed the camera choice, alternative more user-
friendly methods could be considered in the future, e.g.
use of mobile phone cameras; however, these would
need appropriate methods of data protection and ethical
approval. The detailed work instruction for when and
how to photograph the skin sites, including camera set-
tings and the use of a greyscale card was designed to
standardise and optimise the quality of the photographs.
In reality, the work instruction was not always followed,
and this was reflected in the quality of the photographs.
A process of ensuring the training package had been
undertaken by each individual taking the photograph is
recommended for the future.
A strength of this study is that agreement between
paired assessments from a large number of patients was
analysed compared to other studies that have utilised
multiple assessments of a small number of photographs
[18, 19]. The findings are in line with other inter-rater
reliability studies [10, 20, 21] where clinical assessments
undertaken by expert assessors are compared; these are
summarised in the 2019 International Guidelines for
Prevention and Treatment of Pressure Ulcers/Injuries
[3]. However, compared to the wider literature, the sam-
pling of all category 2 PUs plus a 10% random sample
has resulted in a balance in proportions of normal/al-
tered/category 1 and category 2 skin states, which im-
pacts upon interpretation and kappa results.
A further dimension to consider is that the data was
collected and analysed specific to the body site, e.g.
sacrum, buttocks and ischial tuberosities, and side of
body, e.g. left or right heel. It is known that errors can
occur when describing the body sites or transcribing the
side of the body [11, 13]. Levels of agreement may be af-
fected by this type of misclassification, and this is being
explored in methodological research [22].
It is noted that there was more confidence in the as-
sessment of skin sites which were classified as healthy,
altered or category 1 by the blinded expert reviewers. As
the endpoint for this study was the development of a
category ≥2 PU, these skin categories were grouped to-
gether. It is known the consequences for the clinical staff
when a patient develops a category ≥2 PU in terms of
care quality, performance and investigations [13], and
therefore, there is a potential reluctance to take part or
recruit patients to a study which uses this endpoint.
When considering the analysis design of the future cen-
tral blinded expert review, it is recommended that
relooking at the reliability of category 1 PUs is investi-
gated to assess the impact upon its potential use as a pri-
mary endpoint.
The research team set out to assess the potential of
over-reporting and under-reporting of PUs of category
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≥2, but this cannot really be assessed as the central
photographic review is not the gold standard. Rather,
the research team were trying to establish if there were
differences between the arms in the agreement between
central blinded photography review and unblinded clin-
ical assessment that would suggest systematic bias in
under- or over-reporting. Overall, ≈15% of clinically
assessed PUs of category ≥2 were assessed as normal, al-
tered or category 1 by central blind expert photographic
review, and the confidence intervals for the proportion
of agreement of PUs of category ≥2 for each group over-
lapped. One of the concerns in the utility of central
blind photographic review was the ability to distinguish
between non-blanching erythema and a very early cat-
egory 2 PU characterised by a small area of epidermal
loss within a larger area of erythema [5]. Therefore, dif-
ferences would be expected between the two assessment
methods.
The more concerning finding was that photographic
compliance was lower in the APM arm than in the
HSFM arm; in future work, return rates require compli-
ance monitoring by trial arm (without compromising
trial conduct). It is not clear why the compliance was
lower in the APM arm. Further work is required to
understand whether this was related to practical difficul-
ties associated with participant movement on the APM
or systematic bias.
Conclusions
The findings of this study have usefully informed the sci-
entific and practical issues of a technique used to iden-
tify and reduce the risk of bias in medical device trials in
particular when endpoints are changes in skin status and
development of wounds. The reliability of central
blinded expert photography review was found to be ‘very
good’ (PABAK). Photographs have been found to be an
acceptable method of data validation for participants to
support the ‘gold standard’ clinical assessment. Methods
to improve the quality of photographs would increase
the confidence in the assessments.
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